MiMedx Ownership
MDXG Stock | USD 9.16 0.28 2.97% |
Shares in Circulation | First Issued 2007-03-31 | Previous Quarter 148.9 M | Current Value 148.4 M | Avarage Shares Outstanding 343.8 M | Quarterly Volatility 2.1 B |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
MiMedx |
MiMedx Stock Ownership Analysis
About 68.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.97. MiMedx Group had not issued any dividends in recent years. The entity had 3235:10000 split on the 2nd of April 2008. MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. Mimedx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 811 people. To find out more about MiMedx Group contact Joseph Capper at 770 651 9100 or learn more at https://www.mimedx.com.Besides selling stocks to institutional investors, MiMedx also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different MiMedx's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align MiMedx's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
MiMedx Quarterly Liabilities And Stockholders Equity |
|
MiMedx Insider Trades History
Roughly 2.0% of MiMedx Group are currently held by insiders. Unlike MiMedx's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against MiMedx's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of MiMedx's insider trades
MiMedx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MiMedx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MiMedx Group backward and forwards among themselves. MiMedx's institutional investor refers to the entity that pools money to purchase MiMedx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.2 M | Northern Trust Corp | 2024-09-30 | 1.1 M | Royal Bank Of Canada | 2024-09-30 | 1.1 M | Harbor Capital Advisors Inc | 2024-09-30 | 1 M | Royce & Associates, Lp | 2024-09-30 | 972.9 K | Federated Hermes Inc | 2024-09-30 | 906.8 K | Qube Research & Technologies | 2024-09-30 | 894.7 K | Richmond Brothers Inc | 2024-09-30 | 782.7 K | Essex Woodlands Health Ventures | 2024-09-30 | 28.2 M | Blackrock Inc | 2024-06-30 | 9.3 M |
MiMedx Group Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MiMedx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MiMedx Outstanding Bonds
MiMedx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MiMedx Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MiMedx bonds can be classified according to their maturity, which is the date when MiMedx Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
MiMedx Corporate Filings
8K | 16th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 7th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 0.59 | Revenue Per Share 2.447 | Quarterly Revenue Growth 0.029 | Return On Assets 0.1838 |
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.